Kite Pharma's CEO On Cancer-Killing T-Cells: "This Is A Revolution"

The cancer-killing immune cells known as chimeric antigen receptor T-cells (CARTs) have generated excitement in oncology circles for their potential to be highly personalized to individual patients, and their ability in early clinical trials to make previously untreatable tumors melt away. But safety concerns have dogged two of the leading pure-play CART companies—Kite Pharma and Juno Therapeutics—on Wall Street this year, with both seeing their shares drop more than 20% so far.